The primary objective of this study is to evaluate the relative intraoperative improvement in
perfusion between arterial reconstruction and sympathectomies with quantitative ICG. A
minimum of 40 patients, 20 Sympathectomy Prior to Bypass (group 1) and 20 Bypass Prior to
Sympathectomy (group 2), will be recruited for this study. This study will enroll
participants in a one to one randomized study design. There is the potential risk of loss of
confidentiality. The study involves the intraoperative assessment of perfusion by
quantitative ICG. ICG is FDA approved for this usage and will be used according to its
labeling. Assessment involves intraoperative quantitative ICG data, questionnaires, and
patient and physician assessments. There are no additional physical risks associated with
participating in this study over and above that of the planned arterial reconstruction
(bypass) and sympathectomies.The information collected will be kept confidential and will
comply with the HIPAA.